Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
Ann Pharm Fr ; 76(5): 382-390, 2018 Sep.
Artigo em Francês | MEDLINE | ID: mdl-29706468

RESUMO

BACKGROUND: In France, anticoagulants are among the most recommended treatments for serious accidents, particularly among the elderly. OBJECTIVES: The purpose of this study was to evaluate the impact of practical and validated tools designed to reduce the negative effects of vitamin K antagonist (VKA) treatments by assessing patients before and after the tools were implemented. METHODS: An exhaustive before and after multi-centric cohort study was performed in the Agen territory. The follow-up period corresponded to the six-month period post-hospitalization. The principal criterion was the time in the therapeutic range (TTR) at values of 2 to 3 according to the Rosendaal method. RESULTS: The overall time spent in the follow-up period before and after the implementation of the tools in 65- and 74-year-old patients was 58% and 64%, respectively (P=0.584). After the treatments, the TTR in the 85- to 90-year-old patients was 71.1%. An increase was observed in the number of subjects with a TTR≥70% after the implementation of the tools according to age, particularly in the 85- to 90-year-old patients (8 vs. 41; [P=0.01]). Prescription help software revealed a tendency of improvement in TTR values from 61% to 68% (P=0.472). In addition, longer therapeutic periods corresponded to longer patient lifespans (r=0.86). CONCLUSION: This study demonstrates the feasibility and advantages of implementing tools to improve the efficacy of VKA treatment in primary care, particularly for patients from 85 to 90 years old. The results should promote the implementation of this type of treatment method at the national level.


Assuntos
Anticoagulantes/uso terapêutico , Fibrilação Atrial/tratamento farmacológico , Vitamina K/administração & dosagem , Vitamina K/uso terapêutico , Idoso , Idoso de 80 Anos ou mais , Estudos de Coortes , Feminino , França/epidemiologia , Hospitalização , Humanos , Masculino , Fatores de Risco
2.
Mem. Inst. Oswaldo Cruz ; 104(2): 389-392, Mar. 2009. tab
Artigo em Inglês | LILACS | ID: lil-533534

RESUMO

The aim of this study was to determine the incidence of congenital toxoplasmosis (CT) and to assess the performances of prenatal and neonatal diagnoses. From 1994-2005, in Toulouse University Hospital, France, amniocentesis was performed on 352 pregnant women who were infected during pregnancy. All women were treated with spiramycin and pyrimethamine-sulfadoxine when prenatal diagnosis was positive. Among the 275 foetuses with follow-up, 66 (24 percent) were infected. The transmission rates of Toxoplasma gondii were 7 percent, 24 percent and 59 percent in the first, second and third trimesters, respectively. The sensitivity and specificity of PCR on amniotic fluid (AF) were 91 percent and 99.5 percent, respectively. One case was diagnosed by mouse inoculation with AF and six cases were diagnosed by neonatal or postnatal screening. The sensitivity and specificity of PCR on placentas were 52 percent and 99 percent, respectively. The sensitivity of tests for the detection of specific IgA and IgM in cord blood was 53 percent and 64 percent, respectively, and specificity values were 91 percent and 92 percent. In conclusion, PCR performed on AF had the highest levels of sensitivity and specificity for the diagnosis of CT. This permits an early diagnosis of most cases and should be recommended.


Assuntos
Animais , Feminino , Humanos , Recém-Nascido , Gravidez , Complicações Parasitárias na Gravidez/diagnóstico , Toxoplasma , Toxoplasmose Congênita/diagnóstico , Amniocentese , Anticorpos Antiprotozoários/sangue , DNA de Protozoário/análise , Combinação de Medicamentos , Ensaio de Imunoadsorção Enzimática , França/epidemiologia , Hospitais Universitários , Incidência , Imunoglobulina A/sangue , Imunoglobulina G/sangue , Reação em Cadeia da Polimerase , Valor Preditivo dos Testes , Diagnóstico Pré-Natal , Complicações Parasitárias na Gravidez/epidemiologia , Pirimetamina/uso terapêutico , Sensibilidade e Especificidade , Espiramicina/uso terapêutico , Sulfadoxina/uso terapêutico , Toxoplasma/genética , Toxoplasma/imunologia , Toxoplasmose Congênita/tratamento farmacológico , Toxoplasmose Congênita/epidemiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA